Immatics scientists and collaborators present functionally empty and peptide-receptive HLA-A*02:01 molecules that enable quick generation of large libraries of peptide-MHC complexes for TCR screening. Read more here.

A review by two leaders of Immatics’ Cell Therapy CMC Group. Read more here.

Joint publication by MD Anderson Cancer Center and Immatics demonstrating the capability of Immatics to validate a new target class, RNA-edited pHLA targets. Read more here.

First publication on the GAPVAC actively personalized vaccine trial conducted by a consortium led by Immatics. The warehouse approach pioneered in GAPVAC was the blueprint for the ongoing ACTolog® clinical trial by Immatics, which applies the multi-target warehouse approach for the first time in ACT. Read more here.

First publication on the proprietary IMADetect™ target biomarker screening platform by Immatics as used in all ongoing ACT trials. Immatics uses a unique approach setting the qPCR threshold for each target guided by XPRESIDENT® mass spectrometry. Read more here.

Demonstration of Immatics’ capabilities in a collaboration with Genentech to validate neoantigens. Read more here.

Application of the XPRESIDENT® platform on the therapeutic cancer vaccine IMA901. Development of IMA901 (and of all other cancer vaccines) has been discontinued. However, the paper demonstrates the outstanding capabilities to pioneer biomarker-driven clinical development – as also done in the ongoing Adoptive Cell Therapy (ACT) trials. Read more here.

The original paper by Toni Weinschenk, Co-founder and Chief Innovation Officer of Immatics on the XPRESIDENT® target discovery platform. Read more here.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.